Vol 25, No 1 (2018)
Letters to the Editor — Clinical cardiology
Published online: 2018-02-27

open access

Page views 1588
Article views/downloads 1428
Get Citation

Connect on Social Media

Connect on Social Media

Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality

Maria Asuncion Esteve-Pastor12, Esteban Orenes-Piñero12, Vanessa Roldán3, Javier Lacunza-Ruiz12, Mariano Valdés12, Francisco Marín12
Pubmed: 29512103
Cardiol J 2018;25(1):151-154.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Gianstefani S, Douiri A, Delithanasis I, et al. Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention. Am J Cardiol. 2014; 113(7): 1111–1116.
  2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569–2619.
  3. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009; 374(9706): 1967–1974.
  4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
  5. Roldán V, Marín F. The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thromb Haemost. 2015; 113(4): 671–673.
  6. Lip G, Freedman B, De Caterina R, et al. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017; 117(7): 1230–1239.
  7. Levy JH, Spyropoulos AC, Samama CM, et al. Direct oral anticoagulants: new drugs and new concepts. JACC Cardiovasc Interv. 2014; 7(12): 1333–1351.
  8. Esteve-Pastor MA, Roldán V, Valdés M, et al. The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2016; 14(2): 177–187.
  9. Ruiz-Ortiz M, Bertomeu V, Cequier Á, et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost. 2015; 114(4): 695–701.
  10. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest. 2013; 144(5): 1555–1563.
  11. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
  12. Turpie AGG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011; 105(3): 444–453.
  13. Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1): 9–19.
  14. Orenes-Piñero E, Esteve-Pastor MA, Valdés M, et al. Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation. Drug Discov Today. 2017; 22(10): 1565–1571.
  15. Lip GYH, Hammerstingl C, Marin F, et al. X-TRA study and CLOT-AF registry investigators. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016; 178: 126–134.
  16. Makrides CA. Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy. BMJ Case Rep. 2016; 2016.